FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to	STA
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

ATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Galdes Alphonse</u>						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]										neck	all applic Directo	tor		10% Owner	
(Last) BIOGEN 225 BINI	•	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/15/2020							X Officer (give title Other (specify below) EVP Pharmaceutical Oper & Tech									
(Street) CAMBR (City)			02142 (Zip)		_ 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)							Lin	ndividual or Joint/Group Filing (Check Applicable a) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
. ,,	`		le I - Nor	n-Deriv	/ative	e Se	curit	ies Ac	cau	ired. I	Dist	osed o	of. or	Ben	eficial	llv (Owned	<u> </u>			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date,		e,	3. Transaction Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3,			d (A) or	Ī	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount	(/	A) or O)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock			02/1	2/15/2020					M		441	441 A		\$0	\$0 2,67		72.264		D	
Common Stock			02/1	15/2020					F		130		D	\$33	\$333 2,5		542.264		D		
Common Stock															969.366			1 1	By spouse		
		7	able II -									sed of				/ O	wned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) if any (Month/Day/Year)				Date, Transaction Code (Ins						Date Exe piration onth/Day	Amount of			De Se	Price of crivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Dat	te ercisabl		xpiration ate	Title		Amount or Number of Shares						
Restricted Stock Unit	\$0	02/15/2020			M			441		(1)	02	2/15/2020	Comm		441		\$0	333		D	
Restricted Stock Unit	\$0	02/15/2020			J	J		333 ⁽²⁾		(1)	02	2/15/2020 Common Stock 3		333		\$0 0			D		

Explanation of Responses:

/s/ Suzanne Murray, Attorney in Fact for Alphonse Galdes

02/19/2020

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

^{2.} This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.